S-1/A: MiniMed Group Files S-1/A for IPO, Reveals Strong Growth Amidst Mounting Losses

MiniMed Group, a global leader in diabetes technology, filed an S-1/A for its initial public offering of 28 million shares, showcasing robust revenue growth and product innovation despite reporting significant net losses and operational challenges.

Summary

• MiniMed Group, Inc. is preparing for an Initial Public Offering (IPO) of 28,000,000 shares of common stock, with an estimated price range of $25.00 to $28.00 per share, and plans to list on Nasdaq under the symbol MMED.
• The company is a global medical technology provider specializing in diabetes management, offering integrated solutions including insulin pumps, continuous glucose monitoring (CGM) systems, smart insulin pens, and proprietary dosing algorithms.
• For the six months ended October 24, 2025, net sales were $1,475 million, a 13.1% increase year-over-year, with international sales growing 19.7% and U.S. sales remaining relatively flat.
• Preliminary unaudited estimates for the three months ended January 23, 2026, project net sales of $790 million, a 15.0% increase from the prior year, but a net loss between $(106) million and $(117) million, significantly higher than the $(7) million loss in the comparable prior period.
• For the nine months ended January 23, 2026, preliminary unaudited estimates show net sales of $2,265 million, a 13.7% increase, and a net loss between $(126) million and $(139) million, compared to $(30) million in the prior year.
• The company reported a net loss of $(198) million for fiscal year 2025, compared to $(107) million in fiscal year 2024, and $(92) million in fiscal year 2023.
• Adjusted EBITDA for the six months ended October 24, 2025, was $128 million, up from $97 million in the prior year period. For fiscal year 2025, Adjusted EBITDA was $253 million, up from $147 million in fiscal year 2024.
• Global CGM Attachment Rate increased to 65% for the six months ended October 24, 2025, from 58% in the prior year period, and to 66% for the nine months ended January 23, 2026, from 59%.
• A pre-tax charge of $118 million was recorded in the quarter ending January 23, 2026, primarily related to non-cash asset write-offs and cash-related third-party contract termination fees and transition costs for a manufacturing agreement.
• Medtronic will retain 90.03% of the voting power post-IPO, making MiniMed Group a "controlled company" under Nasdaq rules.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While the company demonstrates strong revenue growth, market leadership, and a robust product pipeline, the significant and increasing net losses, particularly the preliminary Q3 FY26 estimates, and the $118 million charge related to manufacturing issues, raise concerns about profitability and operational execution.

Positives

• Strong net sales growth: 13.1% for the six months ended October 24, 2025, and an estimated 15.0% for the three months ended January 23, 2026.
• Significant international sales growth: 19.7% for the six months ended October 24, 2025, and an estimated 20.3% for the three months ended January 23, 2026.
• Increasing Global CGM Attachment Rate: Rose to 65% for the six months ended October 24, 2025, and an estimated 67% for the three months ended January 23, 2026, indicating strong adoption of integrated solutions.
• Market leadership: Global leader in insulin pumps by users, servicing more than 640,000 pump users in approximately 80 countries as of October 2025.
• Robust product pipeline: Includes MiniMed Go Smart MDI (expected US launch Spring CY2026), MiniMed Flex Pump (submitted for US FDA, planned US launch Fall CY2026), MiniMed Fit Patch Pump (aim to submit US FDA Fall CY2026), and next-generation Vivera dosing algorithm (US pivotal trial Q1 CY2026).
• Strategic partnerships: Global partnership with Abbott to supply Instinct CGM, expanding customer choice and access to advanced insulin dosing solutions.
• Expanded indications: MiniMed 780G system received U.S. FDA and CE Mark approval for insulin-requiring Type 2 Diabetes patients in July/September 2025.
• Strong clinical outcomes: MiniMed 780G demonstrated superior glycemic control, with 80% of Recommended Optimal Settings (ROS) users achieving >70% Time in Range (TIR) and a clinically significant 1.4% absolute improvement in A1C compared to standard of care.
• High customer satisfaction: MiniMed 780G maintained the number one pump satisfaction in the United States since Q2 2024.
• Significant R&D investment: $236 million in the six months ended October 24, 2025, and $1.3 billion over the last three fiscal years, fueling innovation.
• Extensive intellectual property: Over 2,500 patents and patent applications worldwide as of October 2025, fortifying competitive positioning.
• Highly experienced management team and a purpose-driven global workforce of approximately 8,000 employees.
• New $500 million five-year senior secured revolving credit facility provides financial flexibility.

Negatives

• Significant and increasing net losses: Preliminary unaudited net loss for the three months ended January 23, 2026, is estimated between $(106) million and $(117) million, substantially worse than the $(7) million actual net loss in the prior year period.
• Preliminary unaudited net loss for the nine months ended January 23, 2026, is estimated between $(126) million and $(139) million, compared to $(30) million in the prior year period.
• Gross Profit for the three months ended January 23, 2026, is estimated at $344 million $380 million, which is lower than the actual $395 million in the prior year period.
• A pre-tax charge of $118 million was recorded in the quarter ending January 23, 2026, related to the termination of a third-party manufacturing agreement for Simplera CGMs, contributing to increased losses.
• U.S. pump sales declined by 15% for the six months ended October 24, 2025, and 7% for the nine months ended January 23, 2026, due to delayed Simplera CGM launch and increased competition.
• Production of Simplera CGM products is scaling slower than anticipated due to initial unsuccessful attempts to develop high-volume automated manufacturing lines.
• Pricing pressure on CGMs globally, particularly in certain international markets, is expected to continue and may negatively impact profit margins.
• Increased cost of products sold as a percentage of net sales (43.7% in FY25 vs 41.8% in FY24) due to a higher mix of lower-margin CGMs.
• Significant litigation charges: $17 million in the six months ended October 24, 2025, related to Diabetes Pump Retainer Ring litigation, and $165 million in fiscal year 2025 for a contractual dispute resolution with Blackstone.
• Reliance on sole suppliers for key components, such as infusion sets from Unomedical, which received a U.S. FDA warning letter on January 8, 2026, posing risks of supply disruption and reputational harm.
• Historical financial information may not reflect the results as a standalone public company, and significant incremental costs will be incurred post-separation.
• Medtronic's continued control (90.03% voting power post-IPO) may prevent other stockholders from influencing significant decisions.
• No dividends are expected to be paid on common stock for the foreseeable future.

Risks

• Operating in a highly competitive industry with rapid technological advances, innovations, and scientific discoveries may render products obsolete or less desirable.
• Experiencing pricing pressure for products, particularly CGMs, due to managed care, increased competition, declining reimbursement rates, and direct-to-consumer trends.
• Challenges or delays in the development and manufacturing of new products, including obtaining required government approvals (U.S. FDA, EMA), could compromise competitive position.
• Reduction or interruption in supply or other manufacturing difficulties, including reliance on sole suppliers (e.g., Unomedical's FDA warning letter for infusion sets), could adversely affect manufacturing and sales.
• Products may not achieve or maintain market acceptance due to lack of desired features, failure to convince customers of benefits, or adverse publicity.
• Failure to expand or maintain an effective sales force, predict and adapt to market changes, or develop and maintain relationships with healthcare professionals (HCPs) or intermediaries.
• Interim, top-line, and preliminary data from clinical trials may change, and future market or clinical studies may be unfavorable to products and their efficacy.
• Exposure to a variety of risks associated with global operations, including currency exchange rate fluctuations, healthcare reform legislation, trade restrictions, and political/economic instability.
• Failure to secure or retain adequate coverage or reimbursement for products by government entities or third-party payors, including impacts from the DMEPOS competitive bidding program.
• Unsuccessful integration of any acquired businesses or challenges related to strategic initiatives, including divestitures and third-party funding arrangements, could adversely affect the business.
• Potential for significant charges in the future, including contract write-offs and impairments to property, plant, and equipment, goodwill, or other intangible assets.
• Subject to extensive, complex, and changing laws and governmental regulations, including U.S. and international tax laws, anti-corruption laws (U.S. FCPA), and data privacy regulations (HIPAA, CCPA, GDPR, EU AI Act).
• Involvement in litigation, arbitration, and governmental proceedings or investigations, including product liability claims (e.g., Diabetes Pump Retainer Ring litigation) and contractual disputes (e.g., EOFlow arbitration, Blackstone termination).
• Quality problems could lead to recalls or safety alerts, product liability claims, reputational harm, and costly settlements.
• Substantial dependence on patent and other proprietary rights, with risks of infringement, misappropriation, or inability to protect such rights.
• Reliance on the proper function, security, and availability of information technology systems and data, with risks of breaches, cyber-attacks, or other disruptions.
• Limited history of operating as a standalone public company, incurring incremental costs and potentially experiencing less diversification and higher cost of capital.
• Medtronic's continued control of the business and potential conflicts of interest due to shared directors and officers.
• The divestment of Medtronic's remaining equity interest may not occur, or a private sale could result in a change of control without a premium for other shareholders.
• Potential for significant tax liabilities if the tax-free status of certain separation or divestment steps is challenged, and restrictions on corporate transactions to preserve tax-free status.
• Rebranding strategy may not produce intended benefits or could be unfavorably received, and continued use of legacy Medtronic branding could adversely affect reputation.
• The transfer of certain assets and liabilities from Medtronic may not be complete prior to the IPO or require third-party consents, leading to increased expenses or business harm.
• Debt obligations from the Revolving Credit Facility could adversely affect business, results of operations, or financial condition.
• No dividends expected for the foreseeable future, meaning investor returns depend on stock price appreciation.

Future Outlook

The company plans to drive adoption of Automated Insulin Delivery (AID) across its addressable market and expand into additional population segments, including insulin-requiring Type 2 Diabetes patients. It aims to increase its global CGM Attachment Rate with next-generation sensors and leverage strategic partnerships, such as the one with Abbott, to expand CGM options. The pipeline includes next-generation AID and Smart MDI solutions like the MiniMed Go, MiniMed Flex, MiniMed Fit, and the Vivera dosing algorithm, designed to deliver hands-free diabetes management. The company expects to accelerate growth through strategic partnerships and tuck-in acquisitions and aims to achieve profitable growth by optimizing manufacturing efficiencies and expanding premium offerings. A U.S. pivotal trial for the Vivera algorithm is expected to begin in Q1 CY2026, and regulatory submissions for new products are planned through CY2026 and CY2027.

Management Comments

• "Our goal is to accelerate the impact we can have as an independent company focused exclusively on helping insulin-dependent people with diabetes experience more predictable control, greater freedom, and better days while achieving strong outcomes."
• "MiniMed is the only company today that commercializes all three essential components of an AID system – the algorithm, the insulin delivery (pump or pen), and the CGM – on one integrated software platform with a single, unified app. The magic is the algorithm and how it brings automation together, delivering best-in-class outcomes with less work for users, and positioning us to lead the hands-free AID era."
• "The opportunity ahead is to make AID accessible, intuitive, and easy to live with. That is when adoption will truly accelerate."
• "Independence also tightens accountability. We will measure ourselves against clear product milestones, operations KPIs, and real-world evidence. Our financial profile, margin opportunities, and long-term growth plan will also be clearer as a standalone company."
• "We are committed to measuring our success not only by devices sold, but by the reduction of the daily burden and the improvements in Time in Range (TIR) for our patients."

Industry Context

StockSavvy.ai notes that MiniMed Group operates in a rapidly growing diabetes technology market, estimated at over $18 billion and projected to grow at a double-digit CAGR through 2030, driven by increasing adoption of advanced diabetes management technologies like Automated Insulin Delivery (AID). The company's integrated "full-stack" approach, owning all components of AID systems (pumps, CGMs, algorithms), provides a competitive advantage in a market where other players often rely on partnerships. The industry is seeing a shift towards more automated and user-friendly solutions, with clinical guidelines increasingly recommending AID as the standard of care. However, the market also faces intense competition, pricing pressures, and complex regulatory hurdles, which MiniMed Group, with its established global footprint and R&D investment, is positioned to navigate. The emergence of GLP-1s is noted, but MiniMed believes their impact on its core insulin-dependent market will be immaterial.

Comparison to Industry Standards

• MiniMed 780G systems outperformed competing products on Time in Range (TIR) in a 2024 meta-analysis, achieving the highest pooled TIR among tested AID systems.
• MiniMed 780G Recommended Optimal Settings (ROS) users achieved a mean TIR of 79.6%, which was 11.9% higher than Omnipod 5 ROS users (67.7%).
• Overall, MiniMed 780G users (using any settings) achieved an unweighted mean TIR of 73.8%, 13.8% higher than Omnipod 5 users (60.0%).
• MiniMed 780G ROS users maintained a median TIR of 75-78% across pediatric and adult patients, compared to 65-70% for Insulet's Omnipod 5 (lowest glucose target) and 61-72% for Tandem's Control-IQ.
• 80% of MiniMed 780G ROS users achieved the consensus target of TIR over 70%, compared to 46% with the lowest target glucose setting for Insulet's Omnipod 5.
• MiniMed 780G is the only system on the market with published data on Time in Tight Range (TITR) showing >55% in children and adult ROS users as of fiscal year 2025.
• MiniMed 780G has maintained the number one pump satisfaction in the United States since Q2 2024, with a 53% overall satisfaction rating in Q2 2025, compared to Tandem's t:slim X2 (47%), Tandem's Mobi (48%), Insulet's Omnipod 5 (37%), and Beta Bionics iLet Bionic Pancreas (34%).
• MiniMed Group has the largest global footprint among key insulin pump competitors, operating in approximately 80 countries, compared to Insulet (16), Tandem (23), Ypsomed (16), and Beta Bionics (1).
• The incremental cost-effective ratio (ICER) for the MiniMed 780G system is $68,402 per Quality-Adjusted Life Year (QALY) over four years and $38,842 per QALY over a lifetime, which is below the common willingness-to-pay threshold of $100,000 per QALY, comparing favorably to cell therapy ($93,240 per QALY over 20 years) and GLP-1 treatments like tirzepatide ($197,023 per QALY) and semaglutide ($467,676 per QALY).

Management Changes

Corporate Governance

Legal Proceedings

• Diabetes Pump Retainer Ring Litigation: Ongoing and threatened lawsuits in the U.S. and Canada alleging personal injuries, including deaths, caused by Series 600 insulin pumps with allegedly defective clear retainer rings. A $17 million certain litigation charge was recorded in the six months ended October 24, 2025.
• EOFlow International Arbitration: EOFlow Co., Ltd. filed an arbitral claim against Medtronic for a $26 million break-up fee related to a terminated acquisition agreement; the company has asserted an arbitral counterclaim for breaches of contractual representations and warranties.
• Witkin False Claims Act Matter: A qui tam lawsuit filed in May 2011 alleging violations of the False Claims Act in connection with sales of certain insulin pump products from 2007 to 2014 and wrongful termination. The U.S. Department of Justice declined to intervene, and the case is in discovery.
• Italian Payback Litigation: Ongoing litigation regarding Italian payback legislation for medical device expenditures. A $7 million decrease in liability was recorded in the six months ended October 24, 2025, due to a legislative decree reducing amounts for 2015-2018, but litigation for 2019 and beyond is still pending.
• Contract Termination with Blackstone: A $165 million certain litigation charge was recognized in fiscal year 2025 due to the mutual termination of a co-development agreement following a contractual dispute related to an alleged acquisition of a competing product.

Related Party Transactions

• Separation Agreement: Governs the transfer of assets and liabilities from Medtronic to MiniMed Group, including indemnification obligations (potentially uncapped for MiniMed Group) and other aspects of the separation.
• Tax Matters Agreement: Governs tax rights, responsibilities, and obligations, including potential indemnification for tax liabilities related to the separation and divestment. Imposes restrictions on MiniMed Group to preserve tax-free status of certain transactions.
• Employee Matters Agreement: Addresses employment, compensation, and benefits matters for employees transferring from Medtronic, including conversion of Medtronic equity awards to MiniMed Group equity awards.
• Intellectual Property Cross-License Agreements: Provide irrevocable, non-exclusive, worldwide, royalty-free licenses between MiniMed Group and Medtronic for certain intellectual property rights.
• Trademark Agreements: Govern rights and obligations for trademarks, including a transitional trademark cross-license agreement for MiniMed Group to use certain Medtronic-owned marks and a trademark co-existence agreement for the CARELINK brand.
• Transition Services Agreement: Medtronic will provide certain services to MiniMed Group (and vice versa) for a transitional period (generally 1-3 years) at negotiated fees, subject to annual 3% increases and surcharges for extensions.
• Registration Rights Agreement: Grants Medtronic certain registration rights with respect to the shares of MiniMed Group common stock it will own post-IPO.
• Juncos Lease and Services Agreements: MiniMed Group will lease a portion of its Juncos, Puerto Rico facility to Medtronic for up to ten years and provide site maintenance, security, and support services.
• Transition Manufacturing and Supply Agreement: Medtronic will provide manufacturing, fabrication, and testing services for certain components for a transitional period of two years (with a one-year renewal option).
• Intercompany Debt: Part of the IPO proceeds will be used to repay intercompany debt owed to Medtronic under a note.
• Blackstone Co-Development Agreements: MiniMed Group has ongoing development and commercialization plans for MiniMed Flex and MiniMed Fit, with royalty obligations to Blackstone if commercialized. A previously terminated agreement resulted in a $165 million charge in FY25.

Stakeholder Impact

• Shareholders: Potential for long-term value appreciation from growth strategies and innovation, but immediate dilution from the IPO. Risks from Medtronic's continued control, stock price volatility, and the absence of expected dividends.
• Employees: New compensation programs, equity awards, and benefits as a standalone company. Potential for employee turnover or attrition during the separation process.
• Customers (PWD, caregivers, HCPs): Continued access to innovative diabetes management solutions, expanded product choices (e.g., Abbott partnership), and improved user experience. Risks from product quality issues, supply disruptions, or changes in reimbursement policies.
• Suppliers: Continued relationships, but potential for changes as MiniMed Group establishes its standalone supply chain. Risks from reliance on sole suppliers and their regulatory compliance.
• Creditors: New $500 million Revolving Credit Facility and repayment of intercompany debt. Debt obligations could impact financial flexibility and future borrowing capacity.
• Regulatory Authorities: Ongoing compliance requirements and scrutiny, particularly for medical devices, data privacy, and anti-corruption laws, potentially leading to enforcement actions or penalties.

Next Steps

• Complete the IPO and list shares on Nasdaq under the symbol MMED.
• Retain approximately $350 million cash from IPO proceeds for general corporate purposes and repay intercompany debt to Medtronic.
• Continue execution of launches for second-generation AID systems, including the Simplera Sync CGM sensor in the U.S.
• Globally introduce new insulin pump (MiniMed Flex), next-generation Vivera dosing algorithm, improved Simplera Sync CGM sensor, and Instinct.
• Submit MiniMed Flex for CE Mark approval by the end of Q1 CY2026.
• Begin the U.S. pivotal trial for the Vivera algorithm in Q1 CY2026.
• Launch the MiniMed Go Smart MDI system in Spring CY2026 (U.S.) and Q1 CY2026 (EU).
• Launch the MiniMed Flex insulin pump in Fall CY2026 (U.S.).
• Aim to submit the MiniMed Fit patch pump for U.S. FDA approval by Fall CY2026, with a U.S. launch in CY2027.
• Implement a long-term incentive plan (MiniMed LTIP) and an employee stock purchase plan (MiniMed ESPP).
• Establish a post-offering peer group for executive compensation.
• Medtronic intends to make a generally tax-free distribution of its remaining equity interest in MiniMed Group (Divestment) after 180 days from the prospectus date.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' for MiniMed Group. While the company demonstrates strong market positioning, an innovative product pipeline, and significant revenue growth, the substantial and increasing net losses, particularly the preliminary Q3 FY26 estimates, and the $118 million charge related to manufacturing issues, present considerable risks. Investors should monitor the company's ability to achieve profitability, successfully execute its product launches, and manage its transition to a standalone entity before considering a 'buy' recommendation.

Keywords

Diabetes management, Insulin pumps, Continuous Glucose Monitoring (CGM), Smart insulin pens, Automated Insulin Delivery (AID), Medical technology, IPO, SEC filing, Medtronic spin-off, Healthcare, Biotech, Financial performance, Product pipeline, Regulatory approval, Nasdaq, MMED, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Smart Dosing, Vivera algorithm, MiniMed Flex, MiniMed Fit, Simplera Sync, Instinct CGM, CareLink, FDA clearance, CE Mark, Clinical trials, Time in Range (TIR), A1C, Litigation, Capital raise, Corporate governance